Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
Phase 1
Completed
- Conditions
- Amyotrophic Lateral SclerosisHealthy Volunteers
- Interventions
- Drug: [18F]PBR06
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 23
- Registration Number
- NCT03876002
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 6
- Registration Number
- NCT03142724
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 6
- Registration Number
- NCT03082768
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Early Phase 1
Completed
- Conditions
- Progressive Supranuclear PalsyHealthy VolunteersAlzheimer Disease
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 6
- Registration Number
- NCT03080051
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Early Phase 1
Completed
- Conditions
- Alzheimer DiseaseHealthy VolunteersProgressive Supranuclear Palsy
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 12
- Registration Number
- NCT03058965
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Early Phase 1
Completed
- Conditions
- Progressive Supranuclear Palsy (PSP)Alzheimer's Disease (AD)Frontal Temporal Dementia (FTD)Cortical Basal Syndrome (CBS)
- Interventions
- Drug: [18F]MNI-815 (MNI-815)
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 7
- Registration Number
- NCT02531360
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 16
- Registration Number
- NCT02370524
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Phase 1
Completed
- Conditions
- Chronic Traumatic Encephalopathy (CTE)TauopathiesProgressive Supranuclear Palsy (PSP)Alzheimer's Disease (AD)Parkinson's Disease (PD)Frontal Temporal Dementia (FTD)Pick's Disease
- Interventions
- Drug: [18F]T807 ([18F]MNI-777)
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 16
- Registration Number
- NCT02103894
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: [123I]MNI-672 SPECT
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 6
- Registration Number
- NCT01859767
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
Phase 1
Terminated
- Conditions
- Alzheimer Disease
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 2
- Registration Number
- NCT00544453
- Locations
- 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath